229 related articles for article (PubMed ID: 25723097)
1. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
Mühlebach S; Borchard G; Yildiz S
Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
[TBL] [Abstract][Full Text] [Related]
2. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
Mühlebach S
Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
[TBL] [Abstract][Full Text] [Related]
3. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines.
Ehmann F; Sakai-Kato K; Duncan R; Hernán Pérez de la Ossa D; Pita R; Vidal JM; Kohli A; Tothfalusi L; Sanh A; Tinton S; Robert JL; Silva Lima B; Amati MP
Nanomedicine (Lond); 2013 May; 8(5):849-56. PubMed ID: 23656268
[TBL] [Abstract][Full Text] [Related]
4. How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider.
Schellekens H; Stegemann S; Weinstein V; de Vlieger JS; Flühmann B; Mühlebach S; Gaspar R; Shah VP; Crommelin DJ
AAPS J; 2014 Jan; 16(1):15-21. PubMed ID: 24065600
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicines: The magic bullets reaching their target?
Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
[TBL] [Abstract][Full Text] [Related]
6. Updated Regulatory Considerations for Nanomedicines.
Subin TS; Vijayan V; Kumar KJR
Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
[TBL] [Abstract][Full Text] [Related]
7. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
Hock SC; Ying YM; Wah CL
PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicines and Nanosimilars: Looking for a New and Dynamic Regulatory "Astrolabe" Inspired System.
Demetzos C; Kavatzikidou P; Pippa N; Stratakis E
AAPS PharmSciTech; 2020 Jan; 21(2):65. PubMed ID: 31933006
[TBL] [Abstract][Full Text] [Related]
9. Regulatory aspects on nanomedicines.
Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
[TBL] [Abstract][Full Text] [Related]
10. Tackling the challenges of nanomedicines: are we ready?
Hertig JB; Shah VP; Flühmann B; Mühlebach S; Stemer G; Surugue J; Moss R; Di Francesco T
Am J Health Syst Pharm; 2021 Jun; 78(12):1047-1056. PubMed ID: 33599767
[TBL] [Abstract][Full Text] [Related]
11. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.
Neu HM; Alexishin SA; Brandis JEP; Williams AMC; Li W; Sun D; Zheng N; Jiang W; Zimrin A; Fink JC; Polli JE; Kane MA; Michel SLJ
Mol Pharm; 2019 Mar; 16(3):1272-1281. PubMed ID: 30676753
[TBL] [Abstract][Full Text] [Related]
12. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties.
Nijhara R; Balakrishnan K
Nanomedicine; 2006 Jun; 2(2):127-36. PubMed ID: 17292125
[TBL] [Abstract][Full Text] [Related]
13. Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?
Emily M; Ioanna N; Scott B; Beat F
AAPS J; 2018 Aug; 20(5):92. PubMed ID: 30128758
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicines in clinical practice: Are colloidal iron sucrose ready-to-use intravenous solutions interchangeable?
Di Francesco T; Sublet E; Borchard G
Eur J Pharm Sci; 2019 Apr; 131():69-74. PubMed ID: 30742979
[TBL] [Abstract][Full Text] [Related]
15. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
Patel P; Shah J
Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
[TBL] [Abstract][Full Text] [Related]
16. Mapping of the available standards against the regulatory needs for nanomedicines.
Halamoda-Kenzaoui B; Holzwarth U; Roebben G; Bogni A; Bremer-Hoffmann S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1531. PubMed ID: 29923692
[TBL] [Abstract][Full Text] [Related]
17. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks.
Hussaarts L; Mühlebach S; Shah VP; McNeil S; Borchard G; Flühmann B; Weinstein V; Neervannan S; Griffiths E; Jiang W; Wolff-Holz E; Crommelin DJA; de Vlieger JSB
Ann N Y Acad Sci; 2017 Nov; 1407(1):39-49. PubMed ID: 28445611
[TBL] [Abstract][Full Text] [Related]
18. Preclinical hazard evaluation strategy for nanomedicines.
Siegrist S; Cörek E; Detampel P; Sandström J; Wick P; Huwyler J
Nanotoxicology; 2019 Feb; 13(1):73-99. PubMed ID: 30182784
[TBL] [Abstract][Full Text] [Related]
19. Regulating Nanomedicine at the Food and Drug Administration.
Paradise J
AMA J Ethics; 2019 Apr; 21(4):E347-355. PubMed ID: 31012422
[TBL] [Abstract][Full Text] [Related]
20. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
